USA-based Retrophin (OTCQB: RTRX) has signed an agreement to acquire Manchester Pharmaceuticals, a privately-held specialty pharmaceutical company that focuses on treatments for rare diseases.
Under the terms of the deal, Retrophin will pay a total of $62.5 million, including an upfront $29.5 million, plus royalties based on product sales. The transaction is expected to close by March 1, 2014.
Providing revenue guidance for the first time, Retrophin expects 2014 revenues to be in the range of $10 million to $12 million, and 2015 revenues in the range of $19 million to $21 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze